Trial title not recorded
Associated Pulmonary Arterial Hypertension
Enrolment: 50 · Results not recorded
Loading the evidence…
Drug · Endothelin receptor, ET-A/ET-B antagonist (ANTAGONIST; direct interaction; disease efficacy true)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Associated Pulmonary Arterial Hypertension
Enrolment: 50 · Results not recorded
Pulmonary Arterial Hypertension
Enrolment: 100 · Results not recorded
Pulmonary Hypertension
Enrolment: 67 · Results not recorded
Pulmonary Arterial Hypertension
Enrolment: 64 · Results not recorded
Pulmonary Arterial Hypertension
Enrolment: 60 · Results not recorded
Hepatopulmonary Syndrome · Liver Cirrhosis
Enrolment: 6 · Results not recorded
Melanoma
Enrolment: 80 · Results not recorded
Secondary Pulmonary Hypertension · Mitral Stenosis · Congestive Heart Failure
Enrolment: 10 · Results not recorded
Glaucoma · Blood Flow Velocity
Enrolment: 28 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Unilateral pulmonary contusion created by dropping a metal weight onto the chest (blunt thoracic trauma)
Bosentan reduced leukocyte infiltration, alveolar oedema and congestion, lowered malondialdehyde and raised superoxide dismutase, and reduced apoptosis, but did not affect fibrosis development or inducible and endothelial nitric oxide synthase levels.
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.